Baidu
map

肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2020 ESMO临床实践指南：边缘区淋巴瘤的诊断，治疗和随访

2020-01-09 欧洲肿瘤内科学会 Ann Oncol. 2020 Jan;31(1):17-29.

边缘区淋巴瘤

2020年1月，欧洲肿瘤内科学会(ESMO)发布了边缘区淋巴瘤的诊断，治疗和随访指南，文章主要内容涉及边缘区淋巴瘤的发生率和流行病学，诊断以及病理/分子生物学，分期和危险因素评估，治疗，应答评估和随访等。

中文标题：

2020 ESMO临床实践指南：边缘区淋巴瘤的诊断，治疗和随访

英文标题：

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

发布机构：

欧洲肿瘤内科学会

发布日期：

2020-01-09

简要介绍：

2020年1月，欧洲肿瘤内科学会(ESMO)发布了边缘区淋巴瘤的诊断，治疗和随访指南，文章主要内容涉及边缘区淋巴瘤的发生率和流行病学，诊断以及病理/分子生物学，分期和危险因素评估，治疗，应答评估和随访等。

 

拓展指南：与淋巴瘤相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2020 ESMO临床实践指南：边缘区淋巴瘤的诊断，治疗和随访)] GetToolGuiderByIdResponse(projectId=1, id=7cc581c001850393, title=2020 ESMO临床实践指南：边缘区淋巴瘤的诊断，治疗和随访, enTitle=Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., guiderFrom=Ann Oncol. 2020 Jan;31(1):17-29., authorId=null, author=, summary=2020年1月，欧洲肿瘤内科学会(ESMO)发布了边缘区淋巴瘤的诊断，治疗和随访指南，文章主要内容涉及边缘区淋巴瘤的发生率和流行病学，诊断以及病理/分子生物学，分期和危险因素评估，治疗，应答评估和随访等。 , cover=, journalId=null, articlesId=null, associationId=14, associationName=欧洲肿瘤内科学会, associationIntro=欧洲肿瘤内科学会（ESMO，European Society for Medical Oncology )是1975年成立的非盈利组织，是欧洲领先的专业组织，致力于提高肿瘤内科的专业性，推进癌症治疗和护理的多学科诊疗方法。, copyright=0, guiderPublishedTime=Thu Jan 09 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<P>2020年1月，欧洲肿瘤内科学会(ESMO)发布了边缘区淋巴瘤的诊断，治疗和随访指南，文章主要内容涉及边缘区淋巴瘤的发生率和流行病学，诊断以及病理/分子生物学，分期和危险因素评估，治疗，应答评估和随访等。 </P> <P> </P>拓展指南：<strong>与<font color=red>淋巴瘤</font>相关指南：</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=97f5d1c0018a5246" title="NCCN临床实践指南：儿童侵袭性成熟B细胞淋巴瘤（2020.V1）" target=_blank>NCCN临床实践指南：儿童侵袭性成熟B细胞淋巴瘤（2020.V1）</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=4e3ed1c0018a48f9" title="NCCN临床实践指南：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（2020.V4）" target=_blank>NCCN临床实践指南：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（2020.V4）</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=1ae0f1c0018351c1" title="JSH实践指南：血液恶性肿瘤—Ⅱ淋巴瘤：霍奇金淋巴瘤" target=_blank>JSH实践指南：血液恶性肿瘤—Ⅱ淋巴瘤：霍奇金淋巴瘤</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=14ac31c00180e319" title="NCCN临床实践指南：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（2020.V2）" target=_blank>NCCN临床实践指南：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（2020.V2）</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=766511c001e9a594" title="2018 JSH实践指南：血液恶性肿瘤—淋巴瘤：巨球蛋白血症/淋巴浆细胞性淋巴瘤" target=_blank>2018 JSH实践指南：血液恶性肿瘤—淋巴瘤：巨球蛋白血症/淋巴浆细胞性淋巴瘤</a></li> 更多信息请点击：<a href="//m.capotfarm.com/guideline/list.do?q=%E6%B7%8B%E5%B7%B4%E7%98%A4" target=_blank>有关淋巴瘤更多指南</a></ul>, tagList=[TagDto(tagId=49573, tagName=边缘区淋巴瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=2, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7439, appHits=307, showAppHits=50, pcHits=3639, showPcHits=5805, likes=51, shares=16, comments=9, approvalStatus=1, publishedTime=Mon Jan 13 23:56:50 CST 2020, publishedTimeString=2020-01-09, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Jan 13 23:56:50 CST 2020, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 19:23:37 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2020 ESMO临床实践指南：边缘区淋巴瘤的诊断，治疗和随访)])
2020 ESMO临床实践指南：边缘区淋巴瘤的诊断，治疗和随访
下载请点击：
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=996078, encodeId=fd329960e8af, content=期待, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e845489837, createdName=金朝岁月, createdTime=Sun Jul 04 12:46:17 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963405, encodeId=79f8963405fc, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ebf1386919, createdName=118173383, createdTime=Fri May 07 15:01:28 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962553, encodeId=e956962553b0, content=急需了解, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afb95491853, createdName=叶宁, createdTime=Tue May 04 08:23:24 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955328, encodeId=0c459553288f, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc12612169, createdName=yqbs11, createdTime=Thu Apr 08 22:54:43 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883177, encodeId=7bf68831e77f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/f0fd4edbc73e4a3bb55ba748c002f51a/5bc7ce71ddc34e23947febcbe9bcaecd.jpg, createdBy=2a215316349, createdName=1489b237m71暂无昵称, createdTime=Sun Sep 06 22:33:11 CST 2020, time=2020-09-06, status=1, ipAttribution=)]
    2021-07-04 金朝岁月

    期待

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=996078, encodeId=fd329960e8af, content=期待, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e845489837, createdName=金朝岁月, createdTime=Sun Jul 04 12:46:17 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963405, encodeId=79f8963405fc, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ebf1386919, createdName=118173383, createdTime=Fri May 07 15:01:28 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962553, encodeId=e956962553b0, content=急需了解, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afb95491853, createdName=叶宁, createdTime=Tue May 04 08:23:24 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955328, encodeId=0c459553288f, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc12612169, createdName=yqbs11, createdTime=Thu Apr 08 22:54:43 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883177, encodeId=7bf68831e77f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/f0fd4edbc73e4a3bb55ba748c002f51a/5bc7ce71ddc34e23947febcbe9bcaecd.jpg, createdBy=2a215316349, createdName=1489b237m71暂无昵称, createdTime=Sun Sep 06 22:33:11 CST 2020, time=2020-09-06, status=1, ipAttribution=)]
    2021-05-07 118173383

    👍

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=996078, encodeId=fd329960e8af, content=期待, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e845489837, createdName=金朝岁月, createdTime=Sun Jul 04 12:46:17 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963405, encodeId=79f8963405fc, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ebf1386919, createdName=118173383, createdTime=Fri May 07 15:01:28 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962553, encodeId=e956962553b0, content=急需了解, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afb95491853, createdName=叶宁, createdTime=Tue May 04 08:23:24 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955328, encodeId=0c459553288f, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc12612169, createdName=yqbs11, createdTime=Thu Apr 08 22:54:43 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883177, encodeId=7bf68831e77f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/f0fd4edbc73e4a3bb55ba748c002f51a/5bc7ce71ddc34e23947febcbe9bcaecd.jpg, createdBy=2a215316349, createdName=1489b237m71暂无昵称, createdTime=Sun Sep 06 22:33:11 CST 2020, time=2020-09-06, status=1, ipAttribution=)]
    2021-05-04 叶宁

    急需了解

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=996078, encodeId=fd329960e8af, content=期待, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e845489837, createdName=金朝岁月, createdTime=Sun Jul 04 12:46:17 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963405, encodeId=79f8963405fc, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ebf1386919, createdName=118173383, createdTime=Fri May 07 15:01:28 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962553, encodeId=e956962553b0, content=急需了解, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afb95491853, createdName=叶宁, createdTime=Tue May 04 08:23:24 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955328, encodeId=0c459553288f, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc12612169, createdName=yqbs11, createdTime=Thu Apr 08 22:54:43 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883177, encodeId=7bf68831e77f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/f0fd4edbc73e4a3bb55ba748c002f51a/5bc7ce71ddc34e23947febcbe9bcaecd.jpg, createdBy=2a215316349, createdName=1489b237m71暂无昵称, createdTime=Sun Sep 06 22:33:11 CST 2020, time=2020-09-06, status=1, ipAttribution=)]
    2021-04-08 yqbs11

    非常有用

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=996078, encodeId=fd329960e8af, content=期待, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e845489837, createdName=金朝岁月, createdTime=Sun Jul 04 12:46:17 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963405, encodeId=79f8963405fc, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ebf1386919, createdName=118173383, createdTime=Fri May 07 15:01:28 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962553, encodeId=e956962553b0, content=急需了解, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afb95491853, createdName=叶宁, createdTime=Tue May 04 08:23:24 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955328, encodeId=0c459553288f, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc12612169, createdName=yqbs11, createdTime=Thu Apr 08 22:54:43 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883177, encodeId=7bf68831e77f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/f0fd4edbc73e4a3bb55ba748c002f51a/5bc7ce71ddc34e23947febcbe9bcaecd.jpg, createdBy=2a215316349, createdName=1489b237m71暂无昵称, createdTime=Sun Sep 06 22:33:11 CST 2020, time=2020-09-06, status=1, ipAttribution=)]
    2020-09-06 1489b237m71暂无昵称

    学习

    0

相关指南

2018 JSH实践指南：血液恶性肿瘤—淋巴瘤：边缘区淋巴瘤

日本血液学会(JSH,Japanese Society of Hematology) · 2019-08-19

Baidu
map
Baidu
map
Baidu
map